RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of acridine carboxamide in treating patients who have advanced non-small cell lung cancer that cannot be treated with surgery.
OBJECTIVES: I. Determine the effect of acridine carboxamide on objective response, response rate, and duration of response in patients with unresectable, locally advanced, progressive or metastatic non-small cell lung cancer. II. Determine the toxicities and pharmacokinetics of this regimen in these patients. OUTLINE: This is a multicenter study. Patients receive acridine carboxamide IV over 24 hours for 5 days. Treatment repeats every 3 weeks for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 6 weeks until disease progression or commencement of another treatment. PROJECTED ACCRUAL: A total of 14-25 patients will be accrued for this study.
Study Type
INTERVENTIONAL
Purpose
TREATMENT
Enrollment
15
Kaiser Franz Josef Hospital
Vienna, Austria
Rigshospitalet
Copenhagen, Denmark
Centre de Lute Contre le Cancer,Georges-Francois Leclerc
Dijon, France
CHU de la Timone
Marseille, France
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Haemato-Onkologische Praxis und Tagesklinik
Munich, Germany
Istituto Nazionale per lo Studio e la Cura dei Tumori
Naples, Italy
Istituti Fisioterapici Ospitalieri - Roma
Rome, Italy
Hospital Universitario 12 de Octubre
Madrid, Spain